AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26395085 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (50 mg/kg bolus followed by 15 mg/kg/h infusion)
Number of subjects: 80
Study 26395085 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ringer acetate)
Number of subjects: 80
Study 26395085 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 80
Study 24191966 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance training (AET) - 45 minutes of walking/running at 60% heart rate reserve, 3 times per week for 26 weeks.
Number of subjects: 102
Study 24191966 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength endurance training (SET) - 8 machine-based exercises (2 sets of 15 repetitions with 100% of the 20 repetition maximum), 3 times per week for 26 weeks.
Number of subjects: 102
Study 24191966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training).
Number of subjects: 102
Study 24191966 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (AET, SET, and controls).
Number of subjects: 102
Study 21236344 — intervention group
Group type: EXPERIMENTAL
Intervention: exemestane (EXE) 25 mg daily and celecoxib (CXB) 400 mg twice daily (group A)
Number of subjects: 82
Study 21236344 — intervention group
Group type: COMPARATOR
Intervention: exemestane (EXE) 25 mg daily (group B)
Number of subjects: 82
Study 21236344 — intervention group
Group type: COMPARATOR
Intervention: letrozole (LET) 2.5 mg daily (group C)
Number of subjects: 82
Study 19125307 — intervention group
Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 18
Study 19125307 — intervention group
Group type: COMPARATOR
Intervention: Injection therapy
Number of subjects: 18
Study 17512780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25mg
Number of subjects: 32
Study 17512780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15456093 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d ritonavir
Number of subjects: 37
Study 15456093 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d ritonavir
Number of subjects: 37
Study 11466986 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP rapid test group
Number of subjects: 812
Study 11466986 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 812
Study 9126686 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic interferon alpha‐2b
Number of subjects: 100
Study 9126686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8472625 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous human proinsulin
Number of subjects: 6
Study 8472625 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin zinc suspension
Number of subjects: 6
Study 8472625 — intervention group
Group type: COMPARATOR
Intervention: Inactive diluent (control)
Number of subjects: 6
Study 3676211 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean intake 18.4 g/d) for 4 weeks
Number of subjects: 100
Study 3676211 — intervention group
Group type: COMPARATOR
Intervention: Abstinence from alcohol for 4 weeks
Number of subjects: 100
Study 31305949 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused approach (intervention group)
Number of subjects: 41
Study 31305949 — intervention group
Group type: COMPARATOR
Intervention: Existing treatment (control group)
Number of subjects: 41
Study 30439834 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated care
Number of subjects: 0
Study 30439834 — intervention group
Group type: COMPARATOR
Intervention: Non-facilitated care
Number of subjects: 0
Study 30439834 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GPs)
Number of subjects: 0
Study 30439834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health professionals (MHPs)
Number of subjects: 0
Study 27165587 — intervention group
Group type: EXPERIMENTAL
Intervention: PS + continuous inhalation of budesonide aerosol
Number of subjects: 184
Study 27165587 — intervention group
Group type: EXPERIMENTAL
Intervention: PS + budesonide solution
Number of subjects: 184
Study 27165587 — intervention group
Group type: EXPERIMENTAL
Intervention: PS + single inhalation of budesonide aerosol
Number of subjects: 184
Study 27165587 — intervention group
Group type: COMPARATOR
Intervention: PS alone
Number of subjects: 184
Study 24574834 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation during upper gastrointestinal endoscopy
Number of subjects: 20
Study 24574834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propofol)
Number of subjects: 20
Study 22752068 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting
Number of subjects: 0
Study 22752068 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 20962212 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (300 mg, subcutaneously)
Number of subjects: 51
Study 20962212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study 17490781 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 366
Study 17490781 — intervention group
Group type: COMPARATOR
Intervention: Adjusted OAD therapy
Number of subjects: 366
Study 15699946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion with subsequent use of antiarrhythmic drugs for maintenance of sinus rhythm
Number of subjects: 0
Study 15699946 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic drugs (warfarin and aspirin)
Number of subjects: 0
Study 15124545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia between 40 and 45 degrees C
Number of subjects: 0
Study 15124545 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave superficial hyperthermia, thermo ablation using radiofrequencies or high focused ultrasound, loco regional heating by intraperitoneal perfusion or by external circulation
Number of subjects: 0
Study 15124545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermo-sensitive liposomes for carrying and targeting chemotherapeutics and gene therapies
Number of subjects: 0
Study 10912216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 10912216 — intervention group
Group type: COMPARATOR
Intervention: TCA
Number of subjects: 0
Study 10912216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8843528 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 13
Study 8843528 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 13
Study 1604260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser (GaAs)
Number of subjects: 30
Study 1604260 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 30
Study 6331482 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 54
Study 6331482 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (180 mg daily)
Number of subjects: 54
Study 3774444 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 3774444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31720816 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus cisplatin (GP)
Number of subjects: 0
Study 31720816 — intervention group
Group type: COMPARATOR
Intervention: fluorouracil plus cisplatin (FP)
Number of subjects: 0
Study 31283977 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-trial testing
Number of subjects: 0
Study 31283977 — intervention group
Group type: COMPARATOR
Intervention: Adduction testing
Number of subjects: 0
Study 28867319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training on microanastomosis using Silastic tubes
Number of subjects: 10
Study 28867319 — intervention group
Group type: COMPARATOR
Intervention: Didactic and visual training on end‐to‐end microvascular anastomosis
Number of subjects: 10
Study 25555390 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise sessions
Number of subjects: 35
Study 25555390 — intervention group
Group type: COMPARATOR
Intervention: Afternoon exercise sessions
Number of subjects: 35
Study 23848030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziziphus jujuba (ZJ) fruit powder 5 grams three times a day for one month
Number of subjects: 70
Study 23848030 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder 5 grams three times a day for one month
Number of subjects: 70
Study 21798838 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair (CR group)
Number of subjects: 142
Study 21798838 — intervention group
Group type: COMPARATOR
Intervention: Isolated acromioplasty-tenotomy (AT group)
Number of subjects: 142
Study 21798838 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing in CR group
Number of subjects: 142
Study 18292454 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25%
Number of subjects: 60
Study 18292454 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 2% with epinephrine
Number of subjects: 60
Study 16575275 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual lifestyle advice intervention
Number of subjects: 1270
Study 16575275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1270
Study 12601559 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based version of the Strengths and Difficulties Questionnaire (SDQ)
Number of subjects: 214
Study 12601559 — intervention group
Group type: COMPARATOR
Intervention: Paper-based version of the Strengths and Difficulties Questionnaire (SDQ)
Number of subjects: 214
Study 11121909 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg o.m. and tinidazole 500 mg b.d. during the first 3 days of pantoprazole therapy (early group, n=50)
Number of subjects: 100
Study 11121909 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg o.m. and tinidazole 500 mg b.d. during the last 3 days of pantoprazole therapy (late group, n=50)
Number of subjects: 100
Study 9028644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (BC)
Number of subjects: 7
Study 9028644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 7
Study 1532117 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol aerosol (10 micrograms/inhalation), 2 inhalations t.i.d.
Number of subjects: 333
Study 1532117 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (salbutamol) aerosol (100 micrograms/inhalation), 2 inhalations t.i.d.
Number of subjects: 333
Study 1532117 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 333
Study 1532117 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 333
Study 3856692 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil therapy
Number of subjects: 11
Study 3856692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30099422 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic medical treatment and allergen-specific immunotherapy (ASIT)
Number of subjects: 104
Study 30099422 — intervention group
Group type: COMPARATOR
Intervention: Basic medical treatment only
Number of subjects: 104
Study 26644526 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose morphine
Number of subjects: 240
Study 26644526 — intervention group
Group type: COMPARATOR
Intervention: Weak opioids
Number of subjects: 240
Study 24850618 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular training programme (NMT)
Number of subjects: 799
Study 22423133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis continued (n = 452)
Number of subjects: 836
Study 22423133 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole prophylaxis discontinued (n = 384)
Number of subjects: 836
Study 20441717 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine ODT (10 mg od, 8 days)
Number of subjects: 12
Study 20441717 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine OST (10 mg od, 8 days)
Number of subjects: 12
Study 18821366 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image intervention
Number of subjects: 81
Study 18821366 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 81
Study 15828904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate alone
Number of subjects: 50
Study 15828904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate plus vitamin D sterol (calcitriol or alfacalcidol)
Number of subjects: 50
Study 15828904 — intervention group
Group type: COMPARATOR
Intervention: Oral calcium carbonate plus vitamin D sterol
Number of subjects: 50
Study 12478069 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV co‐culture of PBMC
Number of subjects: 40
Study 12478069 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood HIV DNA assay
Number of subjects: 40
Study 12478069 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal biopsy HIV DNA
Number of subjects: 40
Study 12478069 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal biopsy HIV RNA
Number of subjects: 40
Study 9917117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation self-management group based on a structured treatment and teaching program and INR self-monitoring
Number of subjects: 179
Study 9917117 — intervention group
Group type: COMPARATOR
Intervention: Conventional care as provided by family physicians
Number of subjects: 179
Study 7775627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg daily for 1 week)
Number of subjects: 15
Study 7775627 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine (0.125 mg/kg bolus, 0.001 mg.kg‐1.min‐1 infusion)
Number of subjects: 15
Study 2089128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 5
Study 2089128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 35406 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH), 40 mg single dose
Number of subjects: 12
Study 35406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31011711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacog beta pegol (N9‐GP)
Number of subjects: 15
Study 31011711 — intervention group
Group type: COMPARATOR
Intervention: Recombinant factor IX‐Fc fusion protein (rFIXFc)
Number of subjects: 15
Study 29798207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray allergen blocker combined with oral antihistamine (citrate tablets)
Number of subjects: 90
Study 29798207 — intervention group
Group type: COMPARATOR
Intervention: Physiological seawater combined with citrate sheet (control group)
Number of subjects: 90
Study 27565398 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Treatment and Anxiety Management Program (STAMP)
Number of subjects: 384
Study 27565398 — intervention group
Group type: COMPARATOR
Intervention: Standard Cessation Program (SCP)
Number of subjects: 384
Study 24499130 — intervention group
Group type: EXPERIMENTAL
Intervention: Koru mindfulness program
Number of subjects: 90
Study 22261467 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port total laparoscopic hysterectomy (Octoport™)
Number of subjects: 56
Study 22261467 — intervention group
Group type: COMPARATOR
Intervention: Conventional four-port total laparoscopic hysterectomy
Number of subjects: 56
Study 19129341 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual striving
Number of subjects: 180
Study 19129341 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance coping
Number of subjects: 180
Study 19129341 — intervention group
Group type: COMPARATOR
Intervention: Social support
Number of subjects: 180
Study 17195831 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100,000 epinephrine
Number of subjects: 35
Study 17195831 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 35
Study 15164511 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (ST) + amino acids complex (AAC) (one tablet of 70 mg 3 times a day)
Number of subjects: 60
Study 15164511 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (ST) + AAC sublingually (one tablet of 70 mg 3 times a day)
Number of subjects: 60
Study 15164511 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST) + placebo
Number of subjects: 60
Study 11668360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (600 mg oral dose)
Number of subjects: 12
Study 11668360 — intervention group
Group type: EXPERIMENTAL
Intervention: LSS models based on three sampling points (1.5, 4 and 24 h)
Number of subjects: 12
Study 11668360 — intervention group
Group type: EXPERIMENTAL
Intervention: LSS models for bioequivalence assessment
Number of subjects: 12
Study 9482291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isosorbide dinitrate (3 mg bolus administered intravenously every 5 min)
Number of subjects: 110
Study 9482291 — intervention group
Group type: COMPARATOR
Intervention: High-dose furosemide (80 mg bolus administered intravenously every 15 min) plus low-dose isosorbide dinitrate (1 mg/h, increased every 10 min by 1 mg/h)
Number of subjects: 110
Study 9482291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isosorbide dinitrate
Number of subjects: 110
Study 9482291 — intervention group
Group type: COMPARATOR
Intervention: High-dose furosemide plus low-dose isosorbide dinitrate
Number of subjects: 110
Study 8305277 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at a dose of 0.1 mM/kg (n = 5)
Number of subjects: 12
Study 8305277 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at a dose of 0.3 mM/kg (n = 7)
Number of subjects: 12
Study 8305277 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine at a dose of 0.1 mM/kg (n = 6)
Number of subjects: 12
Study 3071485 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus moderate exercise (3-mile walk, twice a week group sessions, once a week individual sessions)
Number of subjects: 25
Study 3071485 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (3-mile walk, 3 times/week group sessions, once a week individual sessions)
Number of subjects: 25
Study 3071485 — intervention group
Group type: COMPARATOR
Intervention: Diet only (maintain current low level of activity)
Number of subjects: 25
Study 29982544 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 2 × 1000 mg/d omega-3 fatty acid and 50,000 IU/biweekly cholecalciferol supplement
Number of subjects: 53
Study 27046347 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-retriever thrombectomy in combination with IV t-PA
Number of subjects: 0
Study 27046347 — intervention group
Group type: COMPARATOR
Intervention: IV t-PA alone
Number of subjects: 0
Study 24856854 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based self‐management exercise and diet intervention program (n=29)
Number of subjects: 59
Study 24856854 — intervention group
Group type: COMPARATOR
Intervention: 50‐page educational booklet on exercise and diet (n=28)
Number of subjects: 59
Study 22512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 0 mg cm(‐2) thickness
Number of subjects: 37
Study 22512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 0.5 mg cm(‐2) thickness
Number of subjects: 37
Study 22512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 1 mg cm(‐2) thickness
Number of subjects: 37
Study 22512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 1.5 mg cm(‐2) thickness
Number of subjects: 37
Study 22512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 2 mg cm(‐2) thickness
Number of subjects: 37
Study 20080810 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born at 37 weeks gestation
Number of subjects: 13824
Study 20080810 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born at 38 weeks gestation
Number of subjects: 13824
Study 20080810 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born at 42 weeks gestation
Number of subjects: 13824
Study 20080810 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born at 43 weeks gestation
Number of subjects: 13824
Study 20080810 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born small for gestational age (<10th percentile)
Number of subjects: 13824
Study 20080810 — intervention group
Group type: COMPARATOR
Intervention: Children born large for gestational age (>90th percentile)
Number of subjects: 13824
Study 18843942 — intervention group
Group type: EXPERIMENTAL
Intervention: Five sessions of Behavioral Counseling
Number of subjects: 46
Study 18843942 — intervention group
Group type: COMPARATOR
Intervention: One session of Behavioral Counseling
Number of subjects: 46
Study 16210713 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMN group)
Number of subjects: 197
Study 16210713 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid supplementation (IFA group)
Number of subjects: 197
Study 12126264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan monotherapy (40 or 80 mg)
Number of subjects: 888
Study 12126264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan + HCTZ 12.5 mg
Number of subjects: 888
Study 12126264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan + HCTZ 25 mg
Number of subjects: 888
Study 12126264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan + another antihypertensive + HCTZ
Number of subjects: 888
Study 12126264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan monotherapy
Number of subjects: 888
Study 12126264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan + HCTZ
Number of subjects: 888
Study 12126264 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 888
Study 8788268 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN
Number of subjects: 44
Study 8788268 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 44
Study 1701072 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU bolus before surgery, continuous infusion of 5 x 10(5) KIU/h during surgery, and additional 2 x 10(6) KIU to pump prime)
Number of subjects: 40
Study 1701072 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo treatment)
Number of subjects: 40